Alfa Cytology Integrates Radiolabeling and Characterization for Advanced Radiopharmaceutical Development

As the development of targeted radiopharmaceuticals and antibody-drug conjugates (ADCs) accelerates, Alfa Cytology has significantly enhanced its service portfolio. The company now offers an integrated suite of custom radiolabeling for ADCs and targeted radiopharmaceuticals alongside comprehensive Radiopharmaceutical Physicochemical Characterization CRO services. This strategic integration provides more robust research and development support for biotechnology and pharmaceutical companies, advancing precision medicine.

Successful radiopharmaceutical development requires more than just initial radiolabeling. Key attributes like radiochemical purity, stability, lipophilicity, and target-binding capability require thorough evaluation. Alfa Cytology has strengthened its technology platforms to systematically assess these critical quality attributes, ensuring high-quality radiolabeled products and reliable data for candidate evaluation. This improves development efficiency and minimizes research uncertainties.

Alfa Cytology's enhanced offerings include custom radiolabeling for diverse compounds—antibodies, ADCs, peptide therapeutics, and small molecules—utilizing various radionuclides for diagnostic and therapeutic applications. Physicochemical characterization services cover essential parameters like radiochemical purity, stability, LogP/LogD, and immunoreactivity. This integrated approach empowers research teams to comprehensively evaluate candidate properties, accelerating the advancement of innovative radiopharmaceuticals and targeted therapies.